| Autor: |
Bao Li, Haoran Niu, Xiaoyun Zhao, Xiaoyu Huang, Yu Ding, Ke Dang, Tianzhi Yang, Yongfeng Chen, Jizhuang Ma, Xiaohong Liu, Keda Zhang, Huichao Xie, Pingtian Ding |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Asian Journal of Pharmaceutical Sciences, Vol 19, Iss 2, Pp 100891- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1818-0876 |
| DOI: |
10.1016/j.ajps.2024.100891 |
| Popis: |
Anti-tumor angiogenesis therapy, targeting the suppression of blood vessel growth in tumors, presents a potent approach in the battle against cancer. Traditional therapies have primarily concentrated on single-target techniques, with a specific emphasis on targeting the vascular endothelial growth factor, but have not reached ideal therapeutic efficacy. In response to this issue, our study introduced a novel nanoparticle system known as CS-siRNA/PEITC&L-cRGD NPs. These chitosan-based nanoparticles have been recognized for their excellent biocompatibility and ability to deliver genes. To enhance their targeted delivery capability, they were combined with a cyclic RGD peptide (cRGD). Targeted co-delivery of gene and chemotherapeutic agents was achieved through the use of a negatively charged lipid shell and cRGD, which possesses high affinity for integrin αvβ3 overexpressed in tumor cells and neovasculature. In this multifaceted approach, co-delivery of VEGF siRNA and phenethyl isothiocyanate (PEITC) was employed to target both tumor vascular endothelial cells and tumor cells simultaneously. The co-delivery of VEGF siRNA and PEITC could achieve precise silencing of VEGF, inhibit the accumulation of HIF-1α under hypoxic conditions, and induce apoptosis in tumor cells. In summary, we have successfully developed a nanoparticle delivery platform that utilizes a dual mechanism of action of anti-tumor angiogenesis and pro-tumor apoptosis, which provides a robust and potent strategy for the delivery of anti-cancer therapeutics. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
